Article Text

Download PDFPDF

O35 B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis
  1. Richard Furie1,
  2. Matthew D Cascino2,
  3. Jay P Garg2,
  4. Gustavo Aroca3,
  5. Analía Alvarez4,
  6. Hilda Fragoso-Loyo5,
  7. Elizabeth Zuta Santillán6,
  8. Ana Malvar7,
  9. Paul G Brunetta2,
  10. Thomas Schindler8,
  11. Cary Michael Donna Looney2,
  12. Imran Hassan9 and
  13. Brad H Rovin10
  1. 1Northwell Health Great Neck, New York
  2. 2Genentech, Inc., South San Francisco, USA
  3. 3Simon Bolivar University y Clinica de la Costa, Barranquilla, Colombia
  4. 4CEMIC, Buenos Aires, Argentina
  5. 5Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
  6. 6Instituto de Ginecología y Reproducción, Lima, Peru
  7. 7Organización Maedica de Investigación, Buenos Aries, Argentina
  8. 8F. Hoffmann-La Roche AG, Basel, Switzerland
  9. 9Hoffmann-La Roche Ltd, Mississauga, Canada
  10. 10Ohio State University, Columbus, USA


Background Previous analyses identified associations between the degree of B-cell depletion and response in lupus nephritis (LN). NOBILITY tested whether enhanced B-cell depletion with the type II anti-CD20 mAb obinutuzumab could improve responses in LN.

Methods 126 patients with active Class III/IV LN were randomized to obinutuzumab or placebo infusions in combination with mycophenolate and corticosteroids. Peripheral B-cells were measured using a flow cytometry method with a lower limit of 0.441 cells/μL. Sustained depletion was assessed by flow cytometry measurements at weeks 24 and 52.

Results Obinutuzumab was associated with increased CRR (40% vs. 18%, P=0.007) and ORR (51% vs. 29%, P =0.015) at week 76. Obinutuzumab resulted in rapid and complete depletion of peripheral B-cells, memory and naïve B-cell subsets, and plasmablasts, with 89% of obinutuzumab patients depleted to <0.441 CD19+ cells/μL at week 4. Among obinutuzumab patients, sustained B-cell depletion was associated with greater renal response at week 76 (table 1), although patients who achieved sustained depletion also had lower baseline proteinuria and serum creatinine.

Abstract O35 Table 1

Renal responses at week 76 by depletion status

Conclusions Obinutuzumab, a type II anti-CD20 mAb, induced rapid and complete depletion of peripheral B-cells and B-cell subsets. Similar to previous reports, sustained B-cell depletion was associated with increased renal response. Further evaluation is ongoing to understand the factors associated with achievement of sustained B-cell depletion and renal response.

Acknowledgements This study was funded by F. Hoffmann-La Roche.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.